Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China flag China · Delayed Price · Currency is CNY
11.95
-0.23 (-1.89%)
Sep 10, 2026, 3:04 PM CST

SHE:002900 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
722.64706.971,0711,1531,008910.39
Other Revenue
82.4582.4561.6434.0920.2735.41
805.09789.421,1321,1871,028945.8
Revenue Growth
-21.24%-30.29%-4.58%15.40%8.73%-29.36%
Cost of Revenue
560.83530.78553.88475.55360.34312.86
Gross Profit
244.26258.65578.6711.23668.08632.94
Selling, General & Admin
454.25487.94432.05598.15594.6667.1
Research & Development
84.0293.16105.22112.8189.2799.92
Other Operating Expenses
-0.848.457.3911.115.5314.14
Operating Expenses
534.81586.94545.88719.2699.98782.97
Operating Income
-290.55-328.2932.72-7.97-31.91-150.03
Interest Expense
-26.47-26.47-31.32-22.89-22.62-13.8
Interest & Investment Income
29.3929.1555.4570.5474.24609.35
Currency Exchange Gain (Loss)
0.250.250.510.141.57-0.02
Other Non Operating Income (Expenses)
-30.693.97-0.26-1.06-0.37
EBT Excluding Unusual Items
-290.38-324.6761.3439.5620.22445.12
Impairment of Goodwill
-0.5-0.5----
Gain (Loss) on Sale of Investments
-9.32-11.31-14.6413.3713.87-5.13
Gain (Loss) on Sale of Assets
-0.97-0.520.19-2.61-13.31-1.92
Asset Writedown
-11.55-31.09-0-0-2.91-0.68
Legal Settlements
0.190.19----
Other Unusual Items
14.8714.8713.1131.0622.215.45
Pretax Income
-297.67-353.0360.0181.3740.07452.86
Income Tax Expense
-5.05-11.475.0311.313.57103.18
Earnings From Continuing Operations
-292.62-341.5754.9870.0826.5349.68
Minority Interest in Earnings
1.191.943.73.583.711.27
Net Income
-291.43-339.6358.6873.6630.21350.95
Net Income to Common
-291.43-339.6358.6873.6630.21350.95
Net Income Growth
---20.35%143.86%-91.39%1096.77%
Shares Outstanding (Basic)
316317309307302311
Shares Outstanding (Diluted)
316317309307302311
Shares Change
3.96%2.78%0.61%1.61%-2.74%-4.68%
EPS (Basic)
-0.92-1.070.190.240.101.13
EPS (Diluted)
-0.92-1.070.190.240.101.13
EPS Growth
---20.83%140.00%-91.15%1155.56%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-180.64-283.98-315.52-263.8955.42-86.48
Free Cash Flow Per Share
-0.57-0.90-1.02-0.860.18-0.28
Dividend Per Share
--0.2000.2000.1000.320
Dividend Growth
--0%100.00%-68.75%300.00%
Gross Margin
30.34%32.76%51.09%59.93%64.96%66.92%
Operating Margin
-36.09%-41.59%2.89%-0.67%-3.10%-15.86%
Profit Margin
-36.20%-43.02%5.18%6.21%2.94%37.11%
Free Cash Flow Margin
-22.44%-35.97%-27.86%-22.23%5.39%-9.14%
EBITDA
-149.99-195.57133.6390.4365.02-60.22
EBITDA Margin
-18.63%-24.77%11.80%7.62%6.32%-6.37%
D&A For EBITDA
140.55132.71100.9198.4196.9289.81
EBIT
-290.55-328.2932.72-7.97-31.91-150.03
EBIT Margin
-36.09%-41.59%2.89%-0.67%-3.10%-15.86%
Effective Tax Rate
--8.38%13.88%33.87%22.78%
Revenue as Reported
789.42789.421,1321,1871,028945.8
Advertising Expenses
-23.2716.6251.4643.2431.69